Brokerages forecast that Sangamo Therapeutics Inc (NASDAQ:SGMO) will post earnings per share (EPS) of ($0.18) for the current quarter, Zacks reports. Three analysts have made estimates for Sangamo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.22) and the highest estimate coming in at ($0.11). Sangamo Therapeutics reported earnings per share of ($0.14) during the same quarter last year, which would suggest a negative year-over-year growth rate of 28.6%. The company is scheduled to announce its next earnings report on Tuesday, February 27th.
On average, analysts expect that Sangamo Therapeutics will report full year earnings of ($0.73) per share for the current financial year, with EPS estimates ranging from ($0.81) to ($0.65). For the next fiscal year, analysts forecast that the company will post earnings of ($0.73) per share, with EPS estimates ranging from ($1.07) to ($0.01). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.04. The firm had revenue of $11.81 million during the quarter, compared to analyst estimates of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The business’s revenue was up 333.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.27) earnings per share.
Shares of Sangamo Therapeutics (SGMO) opened at $20.55 on Wednesday. The stock has a market cap of $1,736.91, a price-to-earnings ratio of -29.78 and a beta of 2.87. Sangamo Therapeutics has a one year low of $3.65 and a one year high of $22.85. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64.
In related news, VP Curt A. Herberts III sold 11,803 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $18.00, for a total value of $212,454.00. Following the completion of the sale, the vice president now directly owns 27,636 shares of the company’s stock, valued at $497,448. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Curt A. Herberts III sold 16,630 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $16.13, for a total transaction of $268,241.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 89,953 shares of company stock valued at $1,618,193. 5.50% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. raised its holdings in Sangamo Therapeutics by 6.8% in the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 832 shares in the last quarter. Quantbot Technologies LP bought a new position in Sangamo Therapeutics in the third quarter worth about $118,000. Virtu KCG Holdings LLC bought a new position in Sangamo Therapeutics in the second quarter worth about $124,000. Amalgamated Bank bought a new position in Sangamo Therapeutics in the third quarter worth about $158,000. Finally, Great West Life Assurance Co. Can raised its holdings in Sangamo Therapeutics by 150.3% in the third quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock worth $182,000 after purchasing an additional 7,667 shares in the last quarter. 64.22% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Analysts Expect Sangamo Therapeutics Inc (SGMO) to Post -$0.18 EPS” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/14/analysts-expect-sangamo-therapeutics-inc-sgmo-to-post-0-18-eps.html.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.